Comparison of Blood Pressure Medications on Metabolism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00642434
Recruitment Status : Completed
First Posted : March 25, 2008
Last Update Posted : August 25, 2011
Information provided by (Responsible Party):
Kathleen Colleran, University of New Mexico

Brief Summary:

The purpose of this study is to determine if there are differences, (benefits) between carvedilol and metoprolol in the treatment of HTN in patients with type 2 diabetes. Specifically we will be looking at differences in blood pressure and blood sugar control, endothelial function, inflammation, oxidative stress and coagulation.

Subjects will be randomized to one of the two beta-blockers and followed for 5 months. Each subject will undergo 4 inpatient studies where an oral glucose tolerance test will be done, Inflammatory and oxidative stress markers will be measured. Endothelial function will be measured using brachial artery ultrasound and laser skin Doppler

Condition or disease Intervention/treatment Phase
Diabetes Drug: carvedilol Drug: metoprolol Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Carvedilol vs.Metoprolol: A Comparison of Effects on Endothelial Function and Oxidative Stress in Response to Acute Hyperglycemia in Patients With Type 2 Diabetes and Hypertension
Study Start Date : January 2004
Actual Primary Completion Date : June 2008
Actual Study Completion Date : July 2008

Arm Intervention/treatment
Active Comparator: 1
study drug
Drug: carvedilol
Active Comparator: 2
study drug
Drug: metoprolol

Primary Outcome Measures :
  1. change in endothelial function [ Time Frame: 5 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   45 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • not enrolling

Exclusion Criteria:

  • not enrolling

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00642434

United States, New Mexico
Albquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico

Responsible Party: Kathleen Colleran, Professor of Medicine, University of New Mexico Identifier: NCT00642434     History of Changes
Other Study ID Numbers: UNM04094
First Posted: March 25, 2008    Key Record Dates
Last Update Posted: August 25, 2011
Last Verified: August 2011

Keywords provided by Kathleen Colleran, University of New Mexico:
diabetes blood pressure oxidative stress

Additional relevant MeSH terms:
Anti-Arrhythmia Agents
Antihypertensive Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists